PL401409A1 - Myricetin-piracetam co-crystal and process for the preparation thereof - Google Patents
Myricetin-piracetam co-crystal and process for the preparation thereofInfo
- Publication number
- PL401409A1 PL401409A1 PL401409A PL40140912A PL401409A1 PL 401409 A1 PL401409 A1 PL 401409A1 PL 401409 A PL401409 A PL 401409A PL 40140912 A PL40140912 A PL 40140912A PL 401409 A1 PL401409 A1 PL 401409A1
- Authority
- PL
- Poland
- Prior art keywords
- piracetam
- myricetin
- formula
- crystal
- preparation
- Prior art date
Links
- 229960004526 piracetam Drugs 0.000 title abstract 6
- 239000013078 crystal Substances 0.000 title abstract 3
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 abstract 5
- 229940116852 myricetin Drugs 0.000 abstract 4
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 abstract 4
- 235000007743 myricetin Nutrition 0.000 abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 abstract 2
- BNWJOHGLIBDBOB-UHFFFAOYSA-N myristicin Chemical compound COC1=CC(CC=C)=CC2=C1OCO2 BNWJOHGLIBDBOB-UHFFFAOYSA-N 0.000 abstract 2
- 229910000831 Steel Inorganic materials 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 239000013080 microcrystalline material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003880 polar aprotic solvent Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000010959 steel Substances 0.000 abstract 1
Landscapes
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Wynalazek ujawnia kokrysztal mirycetyna - piracetam o wzorze 3 znajdujacy zastosowanie w przemysle farmaceutycznym i/lub kosmetycznym. Wynalazek dotyczy równiez sposobu otrzymywania kokrysztalu mirycetyna - piracetam o wzorze 3 charakteryzujacego sie na tym, ze mirycytyne o wzorze 1 w ilosci od 25 do 50 mg oraz piracetam o wzorze 2 w ilosci od 200 do 300 mg rozpuszcza sie w od 5 do 10 ml, etanolu, po czym calosc miesza sie, przesacza sie, a nastepnie pozostawia sie do powolnego odparowania w temperaturze pokojowej, a po 14 do 21 dniach zbiera sie krysztaly. W innej metodzie sposobu otrzymywania kokrysztalu mirycetyna - piracetam o wzorze 3 w stalowym naczyniu mlyna kulowego umieszcza sie mirycytyne o wzorze 1 i piracetam o wzorze 2 w ilosci stechiometrycznej 1: 1, po czym dodaje sie polarny, aprotyczny rozpuszczalnik 50 ?l na kazde 50 mg mirycetyny, a nastepnie mieszanine poddaje sie mieleniu przez czas od 5 do 45 minut, przy czestosci drgan 50-60 Hz, i tak otrzymany material mikrokrystaliczny suszy sie w temperaturze pokojowej przez okres 12-24 godzin i poddaje sie analizie na dyfraktometrze proszkowym.The invention discloses the myricetin - piracetam formula 3 which is used in the pharmaceutical and / or cosmetics industry. The invention also relates to a method for the preparation of myricetin - piracetam 3, which is characterized in that myricitin 1 in 25 to 50 mg and piracetam 2 in 200 to 300 mg are dissolved in 5 to 10 ml, ethanol, after which the whole is mixed, filtered, and then allowed to slowly evaporate at room temperature, and after 14 to 21 days crystals collect. In another method of obtaining the myricetin - piracetam formula 3 co-crystal, a ball mill is placed in a steel mill with myristicine formula 1 and piracetam formula 2 in a stoichiometric amount of 1: 1, followed by the addition of a polar aprotic solvent of 50 ml for each 50 mg myricetin, and then the mixture is milled for 5 to 45 minutes, with a 50-60 Hz vibration frequency, and the microcrystalline material thus obtained is dried at room temperature for a period of 12-24 hours and analyzed on a powder diffractometer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401409A PL401409A1 (en) | 2012-10-30 | 2012-10-30 | Myricetin-piracetam co-crystal and process for the preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401409A PL401409A1 (en) | 2012-10-30 | 2012-10-30 | Myricetin-piracetam co-crystal and process for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL401409A1 true PL401409A1 (en) | 2013-04-02 |
Family
ID=48040919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL401409A PL401409A1 (en) | 2012-10-30 | 2012-10-30 | Myricetin-piracetam co-crystal and process for the preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL401409A1 (en) |
-
2012
- 2012-10-30 PL PL401409A patent/PL401409A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016006841A (en) | New pesticidal compounds and uses. | |
| BR112012013431A8 (en) | compound, pharmaceutical composition and its use | |
| CL2014000931A1 (en) | Compounds derived from substituted 5,7-imidazo [1,2-c] pyrimidine, inhibitors of jak kinases; Preparation process; pharmaceutical composition; method for the treatment of autoimmune, inflammatory diseases, organ transplant rejection and neoplasms. | |
| PH12012501800A1 (en) | 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor | |
| MX2013005241A (en) | Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same. | |
| MX378555B (en) | Process for preparation of sulfonylurea bile acid derivatives | |
| MX2015011566A (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same. | |
| MX388300B (en) | PROCESS FOR THE PREPARATION OF SULFONYL CARBAMATE BILE ACID DERIVATIVES | |
| MX2009010505A (en) | Pyridine and pyrimidine derivatives as mglur2 antagonists. | |
| PH12013502369A1 (en) | Diazacarbazoles and methods of use | |
| TW200637863A (en) | Organic compounds | |
| CA2894715C (en) | Diazole amides | |
| MX2016001095A (en) | Salts of dasatinib in crystalline form. | |
| MY166378A (en) | Zeoltic materials and methods for their preparation using alkenyltrialkylammonium compounds | |
| EA201170300A1 (en) | CRYSTAL FORMS OF PYRIDINE DERIVATIVE | |
| MA35002B1 (en) | CRYSTALLINE DELTA FORM OF ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| IL220708A (en) | Compounds whose molecule comprises 2-(pheny/heteroaryl)-[1,3]oxazolo[5,4-d]pyrimidine moiety and carboxy-(n-containing heterocyclyl)carbonyl moiety, as well as hydrocarbyl esters thereof, process for their preparation and pharmaceutical compositions comprising them | |
| PL401412A1 (en) | Hemietanolat fisetin-nicotinamide co-crystal and a method for preparing fisetin-nicotinamide co-crystal | |
| PL401410A1 (en) | Myricetin-caffeine co-crystal and a method for preparing mricetin-caffeine co-crystal | |
| PL401414A1 (en) | Baicalein-nicotinamide co-crystal and a method for preparing baicalein-nicotinamide co-crystal | |
| PL401413A1 (en) | Fisetin-isonicotinamide co-crystal and a method for preparing fisetin-isonicotinamide co-crystal | |
| PL401408A1 (en) | Genistein-nicotinamide monohydrate co-crystal and a method for preparing genistein-nicotinamide monohydrate co-crystal | |
| PL407938A1 (en) | Quercetin-nicotinamide cocrystal and methods for preparing quercetin-nicotinamide cocrystal | |
| PL401411A1 (en) | Luteolin-isonicotinamide co-crystal and a method for preparing luteolin-isonicotinamide co-crystal | |
| PL405445A1 (en) | Genistein-isonicotinamide cocrystal and a method for preparing genistein-isonicotinamide cocrystal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |